BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 33875787)

  • 1. High estrogen receptor alpha activation confers resistance to estrogen deprivation and is required for therapeutic response to estrogen in breast cancer.
    Traphagen NA; Hosford SR; Jiang A; Marotti JD; Brauer BL; Demidenko E; Miller TW
    Oncogene; 2021 May; 40(19):3408-3421. PubMed ID: 33875787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An immune-humanized patient-derived xenograft model of estrogen-independent, hormone receptor positive metastatic breast cancer.
    Scherer SD; Riggio AI; Haroun F; DeRose YS; Ekiz HA; Fujita M; Toner J; Zhao L; Li Z; Oesterreich S; Samatar AA; Welm AL
    Breast Cancer Res; 2021 Oct; 23(1):100. PubMed ID: 34717714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estrogen therapy induces an unfolded protein response to drive cell death in ER+ breast cancer.
    Hosford SR; Shee K; Wells JD; Traphagen NA; Fields JL; Hampsch RA; Kettenbach AN; Demidenko E; Miller TW
    Mol Oncol; 2019 Aug; 13(8):1778-1794. PubMed ID: 31180176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts.
    Creighton CJ; Massarweh S; Huang S; Tsimelzon A; Hilsenbeck SG; Osborne CK; Shou J; Malorni L; Schiff R
    Cancer Res; 2008 Sep; 68(18):7493-501. PubMed ID: 18794137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures.
    Kabos P; Finlay-Schultz J; Li C; Kline E; Finlayson C; Wisell J; Manuel CA; Edgerton SM; Harrell JC; Elias A; Sartorius CA
    Breast Cancer Res Treat; 2012 Sep; 135(2):415-32. PubMed ID: 22821401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer.
    Miller TW; Balko JM; Fox EM; Ghazoui Z; Dunbier A; Anderson H; Dowsett M; Jiang A; Smith RA; Maira SM; Manning HC; González-Angulo AM; Mills GB; Higham C; Chanthaphaychith S; Kuba MG; Miller WR; Shyr Y; Arteaga CL
    Cancer Discov; 2011 Sep; 1(4):338-51. PubMed ID: 22049316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ER alpha negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor.
    Fan J; Yin WJ; Lu JS; Wang L; Wu J; Wu FY; Di GH; Shen ZZ; Shao ZM
    J Cancer Res Clin Oncol; 2008 Aug; 134(8):883-90. PubMed ID: 18264725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER
    Formisano L; Stauffer KM; Young CD; Bhola NE; Guerrero-Zotano AL; Jansen VM; Estrada MM; Hutchinson KE; Giltnane JM; Schwarz LJ; Lu Y; Balko JM; Deas O; Cairo S; Judde JG; Mayer IA; Sanders M; Dugger TC; Bianco R; Stricker T; Arteaga CL
    Clin Cancer Res; 2017 Oct; 23(20):6138-6150. PubMed ID: 28751448
    [No Abstract]   [Full Text] [Related]  

  • 9. Estrogen receptor α attenuates therapeutic efficacy of paclitaxel on breast xenograft tumors.
    Chang J; Sui M; Fan W
    Breast Cancer Res Treat; 2012 Aug; 134(3):969-80. PubMed ID: 22374518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategically Timing Inhibition of Phosphatidylinositol 3-Kinase to Maximize Therapeutic Index in Estrogen Receptor Alpha-Positive, PIK3CA-Mutant Breast Cancer.
    Yang W; Hosford SR; Dillon LM; Shee K; Liu SC; Bean JR; Salphati L; Pang J; Zhang X; Nannini MA; Demidenko E; Bates D; Lewis LD; Marotti JD; Eastman AR; Miller TW
    Clin Cancer Res; 2016 May; 22(9):2250-60. PubMed ID: 26733612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Structure-Function Relationship of Angular Estrogens and Estrogen Receptor Alpha to Initiate Estrogen-Induced Apoptosis in Breast Cancer Cells.
    Maximov PY; Abderrahman B; Hawsawi YM; Chen Y; Foulds CE; Jain A; Malovannaya A; Fan P; Curpan RF; Han R; Fanning SW; Broom BM; Quintana Rincon DM; Greenland JA; Greene GL; Jordan VC
    Mol Pharmacol; 2020 Jul; 98(1):24-37. PubMed ID: 32362585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hormonal Regulation of Semaphorin 7a in ER
    Crump LS; Wyatt GL; Rutherford TR; Richer JK; Porter WW; Lyons TR
    Cancer Res; 2021 Jan; 81(1):187-198. PubMed ID: 33122307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fulvestrant (ICI 182,780) sensitizes breast cancer cells expressing estrogen receptor alpha to vinblastine and vinorelbine.
    Sui M; Jiang D; Hinsch C; Fan W
    Breast Cancer Res Treat; 2010 Jun; 121(2):335-45. PubMed ID: 19626437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The DEK oncogene is a target of steroid hormone receptor signaling in breast cancer.
    Privette Vinnedge LM; Ho SM; Wikenheiser-Brokamp KA; Wells SI
    PLoS One; 2012; 7(10):e46985. PubMed ID: 23071688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of CDK8 mediator kinase suppresses estrogen dependent transcription and the growth of estrogen receptor positive breast cancer.
    McDermott MS; Chumanevich AA; Lim CU; Liang J; Chen M; Altilia S; Oliver D; Rae JM; Shtutman M; Kiaris H; Győrffy B; Roninson IB; Broude EV
    Oncotarget; 2017 Feb; 8(8):12558-12575. PubMed ID: 28147342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinome-wide functional screen identifies role of PLK1 in hormone-independent, ER-positive breast cancer.
    Bhola NE; Jansen VM; Bafna S; Giltnane JM; Balko JM; Estrada MV; Meszoely I; Mayer I; Abramson V; Ye F; Sanders M; Dugger TC; Allen EV; Arteaga CL
    Cancer Res; 2015 Jan; 75(2):405-14. PubMed ID: 25480943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aromatase and breast cancer.
    Brodie A; Sabnis G; Jelovac D
    J Steroid Biochem Mol Biol; 2006 Dec; 102(1-5):97-102. PubMed ID: 17113978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RASSF1A inhibits estrogen receptor alpha expression and estrogen-independent signalling: implications for breast cancer development.
    Thaler S; Schmidt M; Schad A; Sleeman JP
    Oncogene; 2012 Nov; 31(47):4912-22. PubMed ID: 22266866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.
    Sanchez CG; Ma CX; Crowder RJ; Guintoli T; Phommaly C; Gao F; Lin L; Ellis MJ
    Breast Cancer Res; 2011 Mar; 13(2):R21. PubMed ID: 21362200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated ERK1/ERK2/estrogen receptor cross-talk enhances estrogen-mediated signaling during long-term estrogen deprivation.
    Martin LA; Farmer I; Johnston SR; Ali S; Dowsett M
    Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S75-84. PubMed ID: 16113101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.